Share on StockTwits

Investment analysts at Clarus started coverage on shares of Tekmira Pharmaceuticals (NASDAQ:TKMR) in a note issued to investors on Thursday. The firm set a “buy” rating and a $22.50 price target on the stock. Clarus’ price target suggests a potential upside of 75.64% from the company’s current price.

A number of other analysts have also recently weighed in on TKMR. Analysts at Maxim Group cut their price target on shares of Tekmira Pharmaceuticals from $29.00 to $23.00 in a research note on Wednesday, June 4th. They now have a “buy” rating on the stock. Analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Tekmira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $31.00 price target on the stock, down previously from $37.00. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $26.63.

Tekmira Pharmaceuticals (NASDAQ:TKMR) traded up 0.63% during mid-day trading on Thursday, hitting $12.81. The stock had a trading volume of 1,294,429 shares. Tekmira Pharmaceuticals has a one year low of $5.08 and a one year high of $31.48. The stock’s 50-day moving average is $11.87 and its 200-day moving average is $15.61.

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing ribonucleic acid (NASDAQ:TKMR) interference (RNAi) therapeutics and providing its lipid nanoparticle (LNP) delivery technology to pharmaceutical partners.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.